[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100191805":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":20,"studyPopulation":21,"armGroups":17,"interventions":17,"overallOfficials":22,"centralContacts":26,"locations":35,"responsibleParty":54,"collaborators":56,"id":61,"slug":17,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":17,"eligibilityCriteria":65,"healthyVolunteers":62,"sex":66,"minAge":67,"maxAge":17,"enrollmentInfo":68,"targetDuration":71,"studyType":72,"phases":17,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":38,"whyStopped":17,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Centers for Disease Control and Prevention","FED",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":17},[9],{"measure":10,"description":11,"timeFrame":12},"The National Amyotrophic Lateral Sclerosis (ALS) Registry","To determine the incidence and prevalence of Amyotrophic Lateral Sclerosis in the US.","1 year",[14],{"measure":15,"description":16,"timeFrame":12},"Risk factors of ALS","To learn more about the potential risk factors for ALS",null,{"allocation":17,"interventionModel":17,"interventionModelDescription":17,"primaryPurpose":17,"observationalModel":19,"timePerspective":19,"maskingInfo":17},"OTHER","The National ALS Registry's Research Notification System allows person with ALS to participate in clinical trials.","ALS cases in the United States",[23],{"name":24,"affiliation":5,"role":25},"Paul Mehta, MD","PRINCIPAL_INVESTIGATOR",[27,31],{"name":24,"role":28,"phone":29,"phoneExt":17,"email":30},"CONTACT","770-488-0556","PMehta1@cdc.gov",{"name":32,"role":28,"phone":33,"phoneExt":17,"email":34},"Kevin Horton, DrPH, MSPH","770-488-1555","dhorton@cdc.gov",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"CDC","RECRUITING","Atlanta","Georgia","30333","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-84.38798,33.749,{"lat":48,"lon":47},[51,52,53],{"name":24,"role":28,"phone":29,"phoneExt":17,"email":30},{"name":32,"role":28,"phone":33,"phoneExt":17,"email":34},{"name":24,"role":25,"phone":17,"phoneExt":17,"email":17},{"type":55,"investigatorFullName":17,"investigatorTitle":17,"investigatorAffiliation":17,"oldNameTitle":17,"oldOrganization":17},"SPONSOR",[57,59],{"name":58,"class":6},"US Department of Veterans Affairs",{"name":60,"class":6},"Centers for Medicare and Medicaid Services","100191805",false,"NCT01772602","The National Amyotrophic Lateral Sclerosis Registry","Inclusion Criteria:\n\n\\- U.S. citizens 18 years of age or older\n\nExclusion Criteria:\n\n\\-","ALL","18 Years",{"count":69,"type":70},30000,"ESTIMATED","5 Years","OBSERVATIONAL","The purpose of this registry is to (A) better describe the incidence and prevalence of Amyotrophic Lateral Sclerosis (ALS) in the United States;(B) examine appropriate factors, such as environmental and occupational, that may be associated with the disease; (C) better outline key demographic factors (such as age, race or ethnicity, gender, and family history of individuals who are diagnosed with the disease) associated with the disease; and (D) better examine the connection between ALS and other motor neuron disorders that can be confused with ALS, misdiagnosed as ALS, and in some cases progress to ALS.",[75],"Amyotrophic Lateral Sclerosis",[75,77,78],"Lou Gehrig's Disease","Motor Neuron Disease","2026-04-24",{"date":81,"type":82},"2026-04-29","ACTUAL",{"date":84,"type":17},"2010-10",{"date":86,"type":70},"2040-12",{"name":5,"class":6},1]